Every material Form 8-K Picard Medical, Inc. has filed with the SEC since October 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Picard Medical's board appointed Richard Fang, Ph.D., as permanent, full-time Chief Executive Officer effective October 28, 2026; he had served as interim CEO since June 18, 2026 and remains Chairman. The filing also discloses related-person loans from a Fang-affiliated entity, and the company had not received the $1.0 million of external funding that would have kept the earliest of those loans from coming due, so they are now payable on terms yet to be determined.
Richard Fang, Ph.D., appointed permanent CEO effective October 28, 2026; salary remains $0.4 million with no new compensation arrangement
Fang-affiliated fund lent $0.5 million at 0% interest under five loans from July 29 to October 16, 2026; no principal repaid as of October 29, 2026
As of October 29, 2026, no external funding of at least $1.0 million received; earliest loans now due on payment terms to be determined
Separate $0.7 million loan from Fang Family Fund I, LLC at 6% interest, due February 28, 2027
Picard Medical, Inc. entered into an agreement on October 20, 2026, under which holders of warrants from its December 2025 private placement surrendered all of those warrants in exchange for 200,000 shares of common stock. The shares were issued October 22, 2026, and no cash changed hands, so the company received no proceeds. Shareholders should note the issuance adds 200,000 shares to the count and removes the warrants' anti-dilution rights.
Warrants were exercisable for 8,187,766 shares before the 1-for-50 reverse split effective July 31, 2026
Warrant Holders exchanged all Warrants for 200,000 shares of common stock; no cash exercise price was paid
Shares were issued October 22, 2026 under a Section 3(a)(9) exemption from registration
Warrants are cancelled, including anti-dilution and other adjustment rights; holders waive specified liquidated damages
Picard Medical, Inc. issued three unsecured convertible notes totaling $1.0 million to three accredited investors on September 30, 2026, maturing September 30, 2027, with 3.0% interest. Conversion is priced at a floor of $4.00 per share, and the filing says conversion could dilute existing stockholders by up to about 250,000 shares of common stock plus an equal number of pre-funded warrants, excluding interest-related shares.
Notes: three unsecured convertible notes, $1.0 million aggregate principal, 3.0% annual interest, maturing September 30, 2027
Conversion price is the higher of $4.00 per share or the prior-day closing price; maximum of 250,000 shares at the $4.00 floor, excluding interest
Each converted share comes with a pre-funded warrant for one additional share at $0.0001 exercise price, up to 250,000 more shares
Issuance is capped at 19.99% of outstanding shares until stockholder approval is obtained, per NYSE American rules
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Picard Medical, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →